Page 9 - Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update

Guideline: Male LUTS/BPH

23. Wilt TJ, Howe RW, Rutks IR, et al. Terazosin for benign prostatic hyperplasia. Cochrane Database Syst 45. Mamoulakis C, Sofras F, de la Rosette J, et al. Bipolar vs. monopolar transurethral resection of the prostate
Rev 2002:CD003851. for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev
24. McConnell JD, Bruskewitz R, Walsh P, et al and the PLESS Study Group. The effect of finasteride on 2014;1:CD009629. https://doi.org/10.1002/14651858.CD009629.pub3
the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic 46. Geavlete B, Georgescu D, Multescu R, et al. Bipolar plasma vaporization vs. monopolar and bipolar TURP:
hyperplasia. N Engl J Med 1998;338:557-63. https://doi.org/10.1056/NEJM199802263380901 A prospective, randomized, long-term comparison. Urology 2011;78:930-5. https://doi.org/10.1016/j.
25. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase urology.2011.03.072
types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41. 47. Muslumanoglu AY, Yuruk E, Binbay M, et al. Transurethral resection of prostate with plasmakinetic
https://doi.org/10.1016/S0090-4295(02)01905-2 energy: 100 months results of a prospective, randomized trial. BJU Int 2012;110:546-9.
26. Anderson JB, Roehrborn CG, Schalken JA, et al. The progression of benign prostatic hyperplasia: Examining https://doi.org/10.1111/j.1464-410X.2011.10770.x
the evidence and determining the risk. Eur Urol 2001;39:390-9. https://doi.org/10.1159/000052475 48. Varkarakis I, Kyriakakis Z, Delis A, et al. Long-term results of open transvesical prostatectomy from
27. Marks L, Roehrborn C, Andriole G. Prevention of benign prostatic hyperplasia disease. J Urol a contemporary series of patients. Urology 2004;64:306-10. https://doi.org/10.1016/j.uro-
2006;176:1299-306. https://doi.org/10.1016/j.juro.2006.06.022 logy.2004.03.033
28. McConnell JD, Roehrborn CG, Oliver OM, et al for the MTOPS Research Group. The long term effect of 49. Lin, Y, Wu X, Xu A, et al. Transurethral enucleation of the prostate vs. transvesical open prostatectomy for
doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. large benign prostatic hyperplasia: A systematic review and meta-analysis of randomized controlled trials.
N Engl J Med 2003;349:2385-96. https://doi.org/10.1056/NEJMoa030656 World J Urol 2016;34:1207-19. https://doi.org/10.1007/s00345-015-1735-9
29. Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin, and combination therapy 50. Autorino R, Zargar H, Mariano MB, et al., Perioperative outcomes of robotic and laparoscopic
on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostate enlargement: simple prostatectomy: A European-American multi-institutional analysis. Eur Urol 2015;68:86-94.
Two-year results from the CombAT study. J Urol 2008;179:616-21. https://doi.org/10.1016/j. https://doi.org/10.1016/j.eururo.2014.11.044
juro.2007.09.084 51. Naspro R, Suardi N, Salonia A, et al. Holmium laser enucleation of the prostate vs. open prostatec -
30. Barkin J, Guimares M, Joacobi G, et al. Alpha blocker therapy can be withdrawn in the majority of men tomy for prostates >70 g: 24-month followup. Eur Urol 2006;50:563-8. https://doi.org/10.1016/j.
following initial combination therapy with the dual 5-alpha reductase inhibitor dutasteride. Eur Urol eururo.2006.04.003
2003;44:461-6. https://doi.org/10.1016/S0302-2838(03)00367-1 52. Gilling PJ, Wilson LC, King CJ, et al. Long-term results of a randomized trial comparing holmium laser
31. Nickel JC, Barkin J, Koch C, et al. Finasteride monotherapy maintains stable lower urinary tract enucleation of the prostate and transurethral resection of the prostate: Results at 7 years. BJU Int
symptoms in men with BPH following cessation of alpha blockers. Can Urol Assoc J 2008;2:16-21. 2012;109:408-11. https://doi.org/10.1111/j.1464-410X.2011.10359.x
https://doi.org/10.5489/cuaj.520 53. Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): Long-term results, reoperation
32. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower rate, and possible impact of the learning curve. Eur Urol 2007;52:1465-72. https://doi.org/10.1016/j.
urinary tract symptoms and overactive bladder: A randomized controlled trial. JAMA 2006;296:2319-28. eururo.2007.04.074
https://doi.org/10.1001/jama.296.19.2319 54. Thomas JA, Tubaro A, Barber N, et al. A multicentre, randomized, non-inferiority trial comparing GreenLight-
33. Tubaro A, Batista JE, Nitti VW, et al. Efficacy and safety of daily mirabegron 50 mg in male patients XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of
with overactive bladder: A critical analysis of five phase 3 studies. Ther Adv Urol 2017;10;9:137-54. benign prostatic obstruction: Two-year outcomes of the GOLIATH study. Eur Urol 2016;69:94-102.
https://doi.org/10.1177/1756287217702797 https://doi.org/10.1016/j.eururo.2015.07.054
34. Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of 55. Ajib K, Mansoura M, Zanaty M, et al. Photoselective vaporization of the prostate with the 180-W XPS-
solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower Greenlight laser: Five-year experience of safety, efficiency, and functional outcomes. Can Urol Assoc J
urinary tract symptoms: Results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol 2018;12:E318-24. http://dx.doi.org/10.5489/cuaj.4895
2015;67:262-70. https://doi.org/10.1016/j.eururo.2014.07.013 56. Ruszat R, Seitz M, Wyler SF, et al. Prospective single-centre comparison of 120-W diode-pumped,
35. Ichihara K, Masumori N, Fukuta F, et al. A randomized controlled study of the efficacy of tamsulosin solid-state, high-intensity system laser vaporization of the prostate and 200-W high-intensive diode-laser
monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic ablation of the prostate for treating benign prostatic hyperplasia. BJU Int 2009;104:820-5. https://
obstruction. J Urol 2015;193:921-6. https://doi.org/10.1016/j.juro.2014.09.091 doi.org/10.1111/j.1464-410X.2009.08452.x
36. Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved 57. Chiang PH, Chen CH, Kang CH, et al. GreenLight HPS laser 120-W vs. diode laser 200-W vapor -
lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, random- ization of the prostate: Comparative clinical experience. Lasers Surg Med 2010;42:624-9.
ized, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-25. https://doi.org/10.1016/j. https://doi.org/10.1002/lsm.20940
eururo.2012.01.013 58. Gross AJ, Netsch C, Knipper S, et al. Complications and early postoperative outcome in 1080 patients
37. Weiss JP, Herschorn S, Albei CD, et al. Efficacy and safety of low dose desmopressin orally disintegrating after thulium vapoenucleation of the prostate: Results at a single institution. Eur Urol 2013;63:859-67.
tablet in men with nocturia: Results of a multicentre, randomized, double-blind, placebo controlled, parallel https://doi.org/10.1016/j.eururo.2012.11.048
group study. J Urol 2013;190:965-72. https://doi.org/10.1016/j.juro.2012.12.112 59. Rausch S, Heider T, Bedke J, et al, Analysis of early morbidity and functional outcome of thulium:
38. Habib FK Wyllie MG. Not all brands are created equal: A comparison of selected components yttrium-aluminum-garnet laser enucleation for benign prostate enlargement: Patient age and prostate
of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004;7:195-200. size determine adverse surgical outcome. Urology 2015;85:182-8. https://doi.org/10.1016/j.uro-
https://doi.org/10.1038/sj.pcan.4500746 logy.2014.10.002
39. Barry MJ, Meleth S, Kreder KH, et al. Effect of increasing doses of saw palmetto on lower urinary tract 60. Lourenco T, Shaw M, Fraser C, et al. The clinical effectiveness of transurethral incision of the
symptoms: A randomized trial. JAMA 2011;306:1344-51. https://doi.org/10.1001/jama.2011.1364 prostate: A systematic review of randomized controlled trials. World J Urol 2010; 28:23-32.
40. Tacklind J, Macdonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database https://doi.org/10.1007/s00345-009-0496-8
Syst Rev 2012;12:Cd001423. https://doi.org/10.1002/14651858.CD001423.pub3 61. de la Rosette J, Laguna MP, Gravas S, et al. Transurethral microwave thermotherapy: The gold standard for
41. Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane minimally invasive therapies for patients with benign prostatic hyperplasia? J Endourol 2003;17:245-51.
Database Syst Rev 2002;1:Cd001044. https://doi.org/10.1089/089277903765444393
42. Cornu JN, Ahyai S, Bachmann AJ, et al. A systematic review and meta-analysis of functional outcomes 62. D’Ancona FC, van der Bij AK, Francisca EA, et al. Results of high-energy transurethral microwave thermo-Results of high-energy transurethral microwave thermo-
and complications following transurethral procedures for lower urinary tract symptoms resulting from therapy in patients categorized according to the American Society of Anesthesiologists operative risk
benign prostatic obstruction: An update. Eur Urol 2015;67:1066-96. https://doi.org/10.1016/j. classification. Urology 1999;53:322-8. https://doi.org/10.1016/S0090-4295(98)00502-0
eururo.2014.06.017 63. Gravas S, Laguna P, Kiemenen LA, et al. Durability of 30-minute high-energy transurethral microwave
43. Reich O, Gratzke C, BackmannA, et al. Morbidity, mortality, and early outcome of transurethral resection therapy for treatment of benign prostatic hyperplasia: A study of 213 patients with and without urinary
of the prostate: A prospective, multicentre evaluation of 10 654 patients. J Urol 2008;180:246-9. retention. Urology 2007;69:854-8. https://doi.org/10.1016/j.urology.2007.01.070
https://doi.org/10.1016/j.juro.2008.03.058 64. Boyle P, Robertson C, Vaughan ED, et al. A meta-analysis of trials of transurethral needle ablation for
44. Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following treating symptomatic benign prostatic hyperplasia. BJU Int 2004;94:83-8. https://doi.org/10.1111/
transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. j.1464-410X.2004.04906.x
Eur Urol 2010;58:384-397. https://doi.org/10.1016/j.eururo.2010.06.005

CUAJ • October 2018 • Volume 12, Issue 10 311